Lauren A. Baldassarre, MD, FACC
Associate Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2024
Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024 PMID: 39221857, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost hoc analysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screenArtificial intelligence and machine learning for cardiovascular computed tomography (CCT): A white paper of the society of cardiovascular computed tomography (SCCT)
Williams M, Weir-McCall J, Baldassarre L, De Cecco C, Choi A, Dey D, Dweck M, Isgum I, Kolossvary M, Leipsic J, Lin A, Lu M, Motwani M, Nieman K, Shaw L, van Assen M, Nicol E. Artificial intelligence and machine learning for cardiovascular computed tomography (CCT): A white paper of the society of cardiovascular computed tomography (SCCT). Journal Of Cardiovascular Computed Tomography 2024 PMID: 39214777, DOI: 10.1016/j.jcct.2024.08.003.Peer-Reviewed Original ResearchAdverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study
Nain P, Stabellini N, Makram O, Rast J, Yerraguntla S, Gopu G, Bhave A, Seth L, Patel V, Jiang S, Malik S, Shetewi A, Montero A, Cullen J, Agarwal N, Wang X, Ky B, Baldassarre L, Weintraub N, Harris R, Guha A. Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study. JNCI Cancer Spectrum 2024, 8: pkae064. PMID: 39115393, PMCID: PMC11368120, DOI: 10.1093/jncics/pkae064.Peer-Reviewed Original ResearchSocial determinants of healthSocial determinants of health scoreSocial determinantsAdverse SDHImpact of social determinants of healthUncontrolled hypertensionAdverse social determinantsDeterminants of healthRisk of uncontrolled hypertensionProspective cohort studyCardio-oncology clinicCancer patientsBlood pressure readingsHypertension riskHypertension controlCohort studySocial isolationUrban residentsClinic blood pressure readingsControlled hypertensionIncreased riskProspective study patientsCox regressionCardio-oncologyHealthGEDATOLISIB ASSOCIATED ACUTE MYOCARDITIS IN A PATIENT WITH BREAST CANCER
Shen M, Khattab M, Akintoye E, Baldassarre L, Kwan J. GEDATOLISIB ASSOCIATED ACUTE MYOCARDITIS IN A PATIENT WITH BREAST CANCER. Journal Of The American College Of Cardiology 2024, 83: 3575. PMID: 39327001, DOI: 10.1016/s0735-1097(24)05565-7.Peer-Reviewed Original ResearchMultimodality Cardiac Imaging and the Imaging Workforce in the United States: Diversity, Disparities, and Future Directions
Bullock-Palmer R, Rosario K, Douglas P, Hahn R, Lang R, Chareonthaitawee P, Srichai M, Ordovas K, Baldassarre L, Burroughs M, Henderson C, Woodard P, Pressoir K, Swaminathan M, Blankstein R, Daubert M. Multimodality Cardiac Imaging and the Imaging Workforce in the United States: Diversity, Disparities, and Future Directions. Circulation Cardiovascular Imaging 2024, 17: e016409. PMID: 38377238, DOI: 10.1161/circimaging.123.016409.Peer-Reviewed Original Research
2023
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang E, Ky B, Lenihan D, Nohria A, Dani S, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure 2023, 12: 67-78. PMID: 37897456, DOI: 10.1016/j.jchf.2023.08.026.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionSGLT2 inhibitor useGuideline-directed medical therapyHeart failureInhibitor useSGLT2 inhibitorsMedical therapyCardiac dysfunctionAntineoplastic therapyAtrial fibrillation/flutterType 2 diabetes mellitusAcute HF exacerbationCox proportional HRsAcute kidney injuryRenal replacement therapyRetrospective cohort analysisIschemic heart diseaseRisk of cardiomyopathyAggregate patient dataTriNetX Research NetworkProportional HRsCause hospitalizationCause mortalityHF exacerbationKidney injuryAtrial fibrosis by cardiac MRI is a correlate for atrial stiffness in patients with atrial fibrillation
Lamy J, Taoutel R, Chamoun R, Akar J, Niederer S, Mojibian H, Huber S, Baldassarre L, Meadows J, Peters D. Atrial fibrosis by cardiac MRI is a correlate for atrial stiffness in patients with atrial fibrillation. The International Journal Of Cardiovascular Imaging 2023, 40: 107-117. PMID: 37857929, PMCID: PMC11378145, DOI: 10.1007/s10554-023-02968-x.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementLA reservoir strainLeft atrial pressureLA volumeReservoir strainLA fibrosisLA strainStiffness indexLA late gadolinium enhancementAtrial stiffness indexMaximal LA volumeAtrial fibrillation cohortLA minimum volumeAtrial tissue fibrosisMaximum LA volumeCardiac MR examsAtrial stiffnessAtrial strainAF ablationAtrial pressureAF cohortAtrial fibrillationAtrial fibrosisPatient subgroupsLGE volumeMultimodality Evaluation of Spontaneous Coronary Artery Dissection in a Patient With Connective Tissue Disease: A Case Report
Shah T, Shah N, Baldassarre L, Freed L, Mojibian H, Shah S. Multimodality Evaluation of Spontaneous Coronary Artery Dissection in a Patient With Connective Tissue Disease: A Case Report. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101125. PMID: 39129904, PMCID: PMC11308843, DOI: 10.1016/j.jscai.2023.101125.Peer-Reviewed Case Reports and Technical NotesScientific document development standards for the society of cardiovascular computed tomography (SCCT): A statement from the SCCT Guidelines Committee
Baldassarre L, Koweek L, Andreini D, Branch K, Brennaman D, Budde R, De La O S, Fairbairn T, Hedgire S, Weir-McCall J, Woodard P, Wong D, Chen M, Committee S. Scientific document development standards for the society of cardiovascular computed tomography (SCCT): A statement from the SCCT Guidelines Committee. Journal Of Cardiovascular Computed Tomography 2023, 17: 459-464. PMID: 37429770, DOI: 10.1016/j.jcct.2023.06.006.Peer-Reviewed Original ResearchQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
Clinical Trials
Current Trials
Advanced Cardiovascular Magnetic Resonance for Detection of Programmed Cell Death Protein-1 Deficient Myocarditis
HIC ID2000023943RolePrincipal InvestigatorPrimary Completion Date10/29/2024Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Lauren Baldassarre, MD, is a cardiologist at Yale Medicine and director of the Cardio-Oncology Program at the Yale Cancer Center.
Cardio-oncology is a relatively new field that helps patients manage the cardiac side effects of therapies they’re receiving for cancer treatment (such as chemotherapy, radiation and immunotherapy). The goal of the cardio-oncology program is to diagnose and treat those side effects as early as possible.
Dr. Baldassarre first became interested in cardio-oncology during her cardiology fellowship, and she decided to pursue and complete an additional year of fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. That fellowship focused on advanced cardiac imaging with cardiac MRI and caring for cancer patients with cardiac questions or complications. It was a way for Dr. Baldassarre to combine her interests in women’s heart disease and cardiac imaging, and introduced her to the field of cardio-oncology. In 2013, she arrived at Yale Medicine and became the director of the cardio-oncology program in 2015.
As the director, Dr. Baldassarre’s goals have been to offer care to any patient who might benefit from cardiovascular risk assessment and monitoring not only at the main hospital, but also at Yale Medicine satellite sites, and to expand research and clinical trials that investigate ways to diagnose cardiac complications from cancer earlier.
When meeting with new patients, Dr. Baldassarre takes a thorough history and physical and completes a cardiovascular risk assessment based on the type of cancer therapy they will be receiving. Patients can also expect to undergo some cardiac imaging as part of that risk assessment.
“I really hope to be able to put patients at ease,” says Dr. Baldassarre. “I know that patients are concerned especially when they’re going through so much already.” She walks them through established monitoring and treatments protocols, which may be used to prevent complications or treat them, if they do arise.
In addition to seeing patients, Dr. Baldassarre researches the cardiac side effects of immunotherapy, one of the most promising therapies for cancer. She is also an associate professor (cardiology) at Yale Medicine.
Clinical Specialties
Fact Sheets
CT Scan for Coronary Artery Disease
Learn More on Yale MedicineHeart Disease in Women
Learn More on Yale MedicineChronic Total Occlusion (CTO)
Learn More on Yale MedicineCoronary Artery Disease (CAD)
Learn More on Yale Medicine
Board Certifications
Cardiovascular Computed Tomography
- Certification Organization
- AB of Nuclear Cardiology
- Original Certification Date
- 2016
Cardiovascular Disease
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2012
Cardiovascular Computed Tomography
- Certification Organization
- Certification Board of Cardiovascular Computed Tomography
- Original Certification Date
- 2012
Yale Medicine News
News & Links
News
- September 18, 2024
Drs. Gallegos and Akintoye Named New Leaders of Yale’s Advanced Cardiac Imaging Fellowship Program
- July 24, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (July 2024)
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- June 09, 2023
Five faculty members receive Innovative Project Award for sarcoidosis research